Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 16, 2024

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2026

Conditions

Kidney CancerRenal Cell CarcinomaRenal Clear Cell Carcinoma

Interventions

DRUG

Anlotinib, Everolimus and Tislelizumab

Anlotinib (PO, QD), Everolimus (PO, QD) and Tislelizumab (IV, Q3W)

Trial Locations (1)

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors

lead

Fudan University

OTHER